Remove In-Vitro Remove Pharmacy Remove Protein
article thumbnail

Are All Excipients Truly Inert? Maybe Not, Suggests New Study

XTalks

Now, results from a new study conducted by researchers at the UC San Francisco (UCSF) School of Pharmacy and the Novartis Institutes for BioMedical Research (NIBR), have challenged drugmakers’ understanding of the effects of excipients. But just how inert are these excipients?

Protein 103
article thumbnail

Best OINTMENT or CREAM for insect bites

Druggist

In this post, I will review the best ointment or cream for insect bites available over the counter and from pharmacies. Products available for insect bites in supermarkets or pharmacies come almost entirely in the form of creams. For many customers, ointment or cream for insect bites is the first line of rescue in stings management.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Top 10 Medical Device Companies in 2023 by Revenue Statistics and Trends

XTalks

As technology continues to revolutionize every sector of our lives, the medical device industry stands at the forefront of this innovation, playing a pivotal role in enhancing patient care, improving diagnostic accuracy and transforming treatment modalities. Note: When it comes to companies that report in foreign currencies, the conversion to U.S.

article thumbnail

U.S. FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™

Pfizer

Current variants of concern can be resistant to treatments that work by binding to the spike protein found on the surface of the SARS-CoV-2 virus. FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™. Tuesday, December 20, 2022 - 04:30pm. Pfizer oral treatment remains available to eligible U.S. In the U.S., approximately 7.6

Drugs 69
article thumbnail

COVID-19 Pandemic Coverage

XTalks

The company’s candidate vaccine, mRNA-1273, is a synthetic messenger RNA that encodes the stabilized SARS-CoV-2 spike protein. The University of Oxford/AstraZeneca partnership, in turn, is testing a viral-vectored coronavirus vaccine that again expresses the spike protein of SARS-CoV-2 virus. The price of that prize is incalculable.

Vaccine 92